[1]邓 浩,朱洪斌,朱 楠,等.TNNT1在晚期非小细胞肺癌中的表达及与患者预后的关系[J].医学信息,2023,36(05):102-107.[doi:10.3969/j.issn.1006-1959.2023.05.019]
　DENG Hao,ZHU Hong-bin,ZHU Nan,et al.The Expression of TNNT1 in Advanced Non-small Cell Lung Cancer and its Relationship with the Prognosis[J].Journal of Medical Information,2023,36(05):102-107.[doi:10.3969/j.issn.1006-1959.2023.05.019]
点击复制

TNNT1在晚期非小细胞肺癌中的表达及与患者预后的关系()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年05期
页码:
102-107
栏目:
论著
出版日期:
2023-03-01

文章信息/Info

Title:
The Expression of TNNT1 in Advanced Non-small Cell Lung Cancer and its Relationship with the Prognosis
文章编号:
1006-1959（2023）05-0102-06
作者:
邓 浩; 朱洪斌; 朱 楠; 等
（安徽医科大学附属巢湖医院呼吸与危重症医学科，安徽 巢湖 238000）
Author(s):
DENG Hao; ZHU Hong-bin; ZHU Nan; et al.
(Department of Respiratory and Critical Care Medicine,Chaohu Hospital of Anhui Medical University,Chaohu 238000,Anhui,China)
关键词:
肌钙蛋白T1; 非小细胞肺癌; 总生存期; 淋巴结转移
Keywords:
Troponin T1; Non-small cell lung cancer; Overall survival; Lymph node metastasis
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2023.05.019
文献标志码:
A
摘要:
目的 探讨肌钙蛋白T1（TNNT1）在晚期非小细胞肺癌中的表达情况及其临床价值。方法 首先使用Ualcan在线分析网站对肿瘤基因组计划（TCGA）中非小细胞肺癌基因表达谱数据和临床数据进行挖掘，探讨TNNT1 mRNA在非小细胞肺癌中的表达情况，分析其与预后的关系；进一步选取安徽医科大学附属巢湖医院2018年1月-2019年9月收治并经病理确诊的晚期非小细胞肺癌80例，采用免疫组织化学染色方法（IHC）检测患者病理样本及正常肺组织中TNNT1蛋白的表达，分析其与临床病理特征及预后的关系。结果 TCGA数据库分析显示，非小细胞肺癌组织中TNNT1 mRNA表达较癌旁正常组织高（P＜0.05），肺腺癌中TNNT1 mRNA高表达的总生存时间较TNNT1 mRNA中低表达的患者短（P＜0.05）；IHC检测显示，TNNT1蛋白在晚期非小细胞肺癌组织中呈高表达，在正常肺组织中呈低表达；TNNT1蛋白的表达水平与淋巴结转移以及TNM分期有关（P＜0.05）；Kaplan-Meier生存分析显示，TNNT1高表达患者的预后不良；Cox回归分析显示，TNNT1的表达水平和TNM分期是影响患者总生存期（OS）及无进展生存期（PFS）的独立危险因素。结论 TNNT1蛋白在晚期非小细胞肺癌中呈异常高表达，并与患者不良预后相关，是影响患者预后的独立危险因素。
Abstract:
Objective To investigate the expression and clinical value of troponin T1 (TNNT1) in advanced non-small cell lung cancer.Methods Firstly, the Ualcan online analysis website was used to mine the gene expression profile data and clinical data of non-small cell lung cancer in the Cancer Genome Atlas (TCGA) to explore the expression of TNNT1 mRNA in non-small cell lung cancer and analyze its relationship with prognosis. Further, 80 patients with advanced non-small cell lung cancer admitted to Chaohu Hospital of Anhui Medical University from January 2018 to September 2019 were selected. Immunohistochemical staining (IHC) was used to detect the expression of TNNT1 protein in pathological samples and normal lung tissues, and its relationship with clinicopathological features and prognosis was analyzed.Results TCGA database analysis showed that the expression of TNNT1 mRNA in non-small cell lung cancer tissues was higher than that in adjacent normal tissues (P<0.05). The overall survival time of patients with high expression of TNNT1 mRNA in lung adenocarcinoma was shorter than that of patients with low expression of TNNT1 mRNA (P<0.05). IHC detection showed that TNNT1 protein was highly expressed in advanced non-small cell lung cancer tissues and lowly expressed in normal lung tissues, the expression level of TNNT1 protein was related to lymph node metastasis and TNM stage (P<0.05). Kaplan-Meier survival analysis showed that patients with high expression of TNNT1 had poor prognosis. Cox regression analysis showed that TNNT1 expression and TNM stage were independent risk factors for overall survival (OS) and progression-free survival (PFS).Conclusion TNNT1 protein is abnormally high expressed in advanced non-small cell lung cancer, which is associated with poor prognosis and is an independent risk factor affecting the prognosis of patients.

参考文献/References:

[1]Sung H,Ferlay J,Siegel RL,et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin,2021,71(3):209-249. [2]Duma N,Santana-Davila R,Molina JR.Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis,andTreatment[J].Mayo Clin Proc,2019,94(8):1623-1640. [3]Imyanitov EN,Iyevleva AG,Levchenko EV.Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives[J].Crit Rev Oncol Hematol,2021,157:103194. [4]Kuroda T,Yasuda S,Nakashima H,et al.Identification of a Gene Encoding Slow Skeletal Muscle Troponin T as a Novel Marker for Immortalization of Retinal Pigment Epithelial Cells[J].Sci Rep,2017,7(1):8163.[5]赵敏超,郭栋,杨于冰,等. TNNT1在骨肉瘤中的表达及其对HOS细胞增殖和迁移的影响[J].山西医科大学学报,2022,53(8):975-980.[6]Wei B,Jin JP.TNNT1, TNNT2, and TNNT3: Isoform genes, regulation, and structure-function relationships[J].Gene,2016,582(1):1-13. [7]Jin JP,Zhang Z,Bautista JA.Isoform diversity, regulation, and functional adaptation of troponin and calponin[J].Crit Rev Eukaryot Gene Expr,2008,18(2):93-124. [8]Barton PJ,Townsend PJ,Brand NJ,et al.Localization of the fast skeletal muscle troponin I gene (TNNI2) to 11p15.5: genes for troponin I and T are organized in pairs[J].Ann Hum Genet,1997,61(Pt 6):519-523.[9]Géraud J,Dieterich K,Rendu J,et al.Clinical phenotype and loss of the slow skeletal muscle troponin T in three new patients with recessive TNNT1 nemaline myopathy[J].J Med Genet,2021,58(9):602-608. [10]Shi Y,Zhao Y,Zhang Y,et al.TNNT1 facilitates proliferation of breast cancer cells by promoting G1/S phase transition[J].Life Sci,2018,208:161-166. [11]Chen Y,Wang J,Wang D,et al.TNNT1, negatively regulated by miR-873, promotes the progression of colorectal cancer[J].J Gene Med,2020,22(2):e3152.[12]Witkiewicz AK,Kumarasamy V,Sanidas I,et al.Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy[J].Trends Cancer,2022,8(9):711-725. [13]Kim BN,Ahn DH,Kang N,et al.TGF-β induced EMT and stemness characteristics are associated with epigenetic regulation in lung cancer[J].Sci Rep,2020,10(1):10597.[14]Hao YH,Yu SY,Tu RS,et al.TNNT1, a prognostic indicator in colon adenocarcinoma, regulates cell behaviors and mediates EMT process[J].Biosci Biotechnol Biochem,2020,84(1):111-117. [15]Gu X,Li B,Jiang M,et al.RNA sequencing reveals differentially expressed genes as potential diagnostic and prognostic indicators of gallbladder carcinoma[J].Oncotarget,2015,6(24):20661-20671. [16]Dyavar SR,Potts LF,Beck G,et al.Transcriptomic approach predicts a major role for transforming growth factor beta type 1 pathway in L-Dopa-induced dyskinesia in parkinsonian rats[J].Genes Brain Behav,2020,19(8):e12690. [17]Lee YS,Choi H,Cho HR,et al.Downregulation of NKG2DLs by TGF-β in human lung cancer cells[J].BMC Immunol,2021,22(1):44. [18]Meng Z,Yuan Q,Zhao J,et al.The m6A-Related mRNA Signature Predicts the Prognosis of Pancreatic Cancer Patients[J].Mol Ther Oncolytics,2020,17:460-470.[19]Deng Y,Xie Q,Zhang G,et al.Slow skeletal muscle troponin T,titin and myosin light chain 3 are candidate prognostic biomarkers for Ewing’s sarcoma[J].Oncol Lett,2019,18(6):6431-6442. [20]Fei X,Kong L,Shi C,et al.Identification of Prognosis-Related Molecular Subgroups and Construction of a Prognostic Prediction Model Using Immune-Related Genes in Pancreatic Cancer[J].J Oncol,2022,2022:7117014.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(05):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(05):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(05):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(05):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[5]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(05):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[6]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(05):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[7]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(05):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[8]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(05):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[9]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
　JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(05):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
[10]杨珑静,马洪波,张献全.抗血管生成药物在非小细胞肺癌中的应用及研究进展[J].医学信息,2019,32(08):58.[doi:10.3969/j.issn.1006-1959.2019.08.018]
　YANG Long-jing,MA Hong-bo,ZHANG Xian-quan.Application and Research Progress of Anti-angiogenic Drugs in Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(05):58.[doi:10.3969/j.issn.1006-1959.2019.08.018]

更新日期/Last Update: 1900-01-01